Headlines

Comeback puts Iraq's Maliki in Trump's crosshairs

By Ahmed Rasheed and Michael Georgy BAGHDAD/DUBAI, Jan 28 (Reuters) - Former Iraqi Prime Minister Nouri al-Maliki, who appeared poised for a remarkable comeback despite accusations he stoked sectarian strife and allowed the rise of Islamic State,now finds himself in U.S.

Iran rejects talks with US amid military 'threats'

Iran on Wednesday rejected holding negotiations with the United States if it makes threats against the Islamic republic, after President Donald Trump refused to rule out military intervention over its deadly crackdown on protests. With a US naval strike group led by an aircraft

The World Sees Trump’s America as a Sad Joke

Last week, as global elites met in Davos to celebrate hard power, the dance world marked the 122nd birthday, on January 22, of George Balanchine, whose life was the result of the greatest failure and collapse of hard power. That failure was caused by Joseph Stalin, who

Donald Trump Is Frightened

The media verdict is in: President Trump has “ softened ” his stance on his paramilitary war on Minneapolis. He struck a “ cooperative tone ” in a call with Minnesota’s Democratic governor, Tim Walz. The administration hopes to “ shift its strategy ” on its ICE raids. Trump is

Data Centers Are Not “Campuses”

In recent months, a particular word has begun to circulate with striking insistence in press releases across the United States. Technology companies and government officials announce the construction of “data center campuses.” Not plants or factories or warehouses or complexes,

5 questions about Trump's ban on investors buying homes

President Trump’s executive order to prevent Wall Street investors from purchasing single-family homes is the administration's most ambitious attempt to address the state of the housing market. The president argued that Wall Street investors have bought a “growing share” of

'Transformative' HIV PrEP shot slowly overcomes cost hurdles

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers' reluctance to cover its exorbitant cost. In the months since, payers are coming around, and more patients have